Biocept

Biocept Short-term Debt

The Short-Term Debt of Biocept (BIOCQ) as of Nov 20, 2026 is 1.73 M USD. In the previous year, Short-Term Debt was 1.51 M USD — a change of 14.91% (higher).

Short-term Debt

1.73 MUSD

YoY

14.91%

Last updated:

Short-Term Debt of Biocept is 2022 1.73 M USD. Short-Term Debt of Biocept was 2021 1.51 M USD. It decreases by 14.91% higher compared to the previous year.

The Biocept Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2015
40,000.00 USD
Jan 1, 2016
80,000.00 USD
Jan 1, 2017
60,000.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
1.57 M USD
Jan 1, 2020
964,000.00 USD
Jan 1, 2021
1.51 M USD
Jan 1, 2022
1.73 M USD
The Biocept Short-term Debt history
YEARShort-term DebtYoY
1.73 MUSD+14.91%
1.51 MUSD+56.54%
964,000.00USD-38.47%
1.57 MUSD—
0.00USD-100.00%
60,000.00USD-25.00%
80,000.00USD+100.00%
40,000.00USD+33.33%
30,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Short-Term Debt of Biocept is 1.73 M USD in 2022.

Short-Term Debt of Biocept changed from 1.51 M USD to 1.73 M USD, representing a 14.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Biocept since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocept

All Key Metrics — Biocept